RxDoctor Payments Data

Ryan Rainer, MD

Family Medicine · Centre, ALNPI 1811916620

Payments from drug & device makers

$5,130in general payments, 2019–2025

Across 367 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$753
  • Lilly USA, LLC$563
  • AstraZeneca$526
  • Novo Nordisk$502
  • Pfizer$466
  • Merck$283
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,130 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$123,222
Medicare patients
307
Services billed
2,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$189,299
MounjaroTirzepatide121$175,268
FarxigaDapagliflozin Propanediol78$80,905
EliquisApixaban63$60,512
TrulicityDulaglutide38$59,749
JardianceEmpagliflozin39$44,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,381
LinzessLinaclotide20$13,876
CreonLipase/Protease/Amylase14$10,745
Repatha SureclickEvolocumab16$8,952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,642
BelsomraSuvorexant15$6,310
Wixela InhubFluticasone Propion/Salmeterol13$5,680
Gabapentin417$5,617
Omeprazole318$5,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$563$235,018159 claims
Novo NordiskOzempic$502$189,299151 claims
AstraZenecaFarxiga, Symbicort$526$84,43793 claims
PfizerEliquis, Premarin, Paxlovid$466$69,01897 claims
Boehringer IngelheimJardiance$109$44,78439 claims
AbbVieLinzess, Creon, Synthroid$753$29,60079 claims
GSKTrelegy Ellipta, Breo Ellipta$170$20,41533 claims
MerckBelsomra$283$6,31015 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$5,309509 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Centre

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →